RTTNews | Sep 13, 2021 06:29AM EDT

06:29 Monday, September 13, 2021 (RTTNews.com) - AzurRx BioPharma, Inc. (AZRX) has agreed to acquire First Wave Bio, Inc. in a stock and cash deal valued at $229 million. AzurRx will change its corporate name to First Wave BioPharma Inc., and will trade common shares on Nasdaq under ticker symbol, FWBI.

First Wave Bio is a clinical-stage biotechnology company specializing in the development of gut-targeted, small molecule therapies for auto-immune inflammatory bowel diseases and other serious conditions.

AzurRx will wholly own all rights to First Wave Bio's formulations of niclosamide, a small molecule drug which features anti-viral and anti-inflammatory properties that are designed to address multiple gastrointestinal conditions.

Read the original article on RTTNews ( https://www.rttnews.com/3225073/azurrx-announces-acquisition-of-first-wave-bio-and-creation-of-first-wave-biopharma.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved